| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/15/2009 | US7589169 Carrier with a metal binding domain, a metal ion, and an active agent; e.g., polylysine with a polyoxyethylene side chain with a polyalkylenepolyaminepolyacetic acid bonded to a transition metal ion bonded to a protein or nucleotide; drug delivery |
| 09/15/2009 | US7589168 Increasing in vivo concentration of A beta peptide, or biologically active fragments or variants thereof within a patient suffering from angiogenic diseases, conditions, or processes |
| 09/15/2009 | US7589157 Multi-arm block copolymers as drug delivery vehicles |
| 09/15/2009 | US7589074 Treating inflammatory joint diseases by inhibiting cadherin-11 mediated cellular function; chronic synovitis, autoimmune diseases, rheumatoid arthritis |
| 09/15/2009 | US7589070 Surface modification for improving biocompatibility |
| 09/15/2009 | US7589065 Catalysis of the cis/trans-isomerisation of secondary amide peptide compounds |
| 09/15/2009 | US7589064 Formulations of ramipril |
| 09/15/2009 | US7589063 Molecules which promote hematopoiesis |
| 09/15/2009 | US7589062 Cytolytic agents; side effect reduction; Kaposi sarcoma |
| 09/15/2009 | US7589061 Tc and Re labeler radioactive glycosylated octreotide derivatives |
| 09/15/2009 | US7589060 Containing fibroblast growth factor or partial peptide active ingredient; promoting follicle growth |
| 09/15/2009 | US7589059 Delivery of molecules and complexes to mammalian cells in vivo |
| 09/15/2009 | US7589058 Ghrelin analogs |
| 09/15/2009 | US7589056 Agent for the prevention and treatment of sexually transmitted diseases-I |
| 09/15/2009 | US7588930 Fusing to the antigen a Listerial truncated ActA protein; listeria vaccine strain |
| 09/15/2009 | US7588919 Polynucleotide encoding an IL-28B polypeptide |
| 09/15/2009 | US7588918 Mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins which has antihepatitis activity |
| 09/15/2009 | US7588915 Isolated genomic polynucleotide fragments from chromosome 7 |
| 09/15/2009 | US7588914 Bacterial Bcl-2 domain-containing polypeptides, encoding nucleic acid molecules, and related methods |
| 09/15/2009 | US7588912 Compositions and methods for preventing and treating anthrax diseases |
| 09/15/2009 | US7588781 oral administering a mixture powders comprising a dissolved whey protein to increase release the bioactive carotenoid, polyphenol, vitamins, flavonoid, isoflavone, ceramide |
| 09/15/2009 | US7588766 Treatment of amyloidogenic disease |
| 09/15/2009 | US7588763 Methods for the prevention against or treatment of diabetes with ETXB and/or insulin |
| 09/15/2009 | US7588762 Streptoccal inhibitor of complement-mediated lysis, protein SIC |
| 09/15/2009 | US7588761 Antibody for use in the treatment and prevention of sepsis, infections, autoimmune and graft-versus-host diseases; biodegradable, biocompatible polymer and human antibody, or an antigen-binding portion thereof, that dissociates from human TNF alpha |
| 09/15/2009 | US7588760 Binds to a denatured collagens but not to native triple helical forms of the collagen; antitumor agents, antimetastasis agents; monoclonal antibodies; drug screening for denatured collagen antagonists |
| 09/15/2009 | US7588759 Compositions comprising sclareol or derivatives thereof and uses thereof |
| 09/15/2009 | US7588758 A genetic vector comprising a promoter linked to an expression cassette able to express a cyclooxygenase protein; treating bone disorder osteoporosis, heterotopic ossification |
| 09/15/2009 | US7588757 Methods of treating Parkinson's disease using recombinant adeno-associated virus virions |
| 09/15/2009 | US7588756 Administering intracoronally a compatible auxiliary or support and a nucleic acid encoding a polypeptide S100A1 protein; increases the systolic Ca2+ release from the sarcoplasmic reticulum and increases the rate of Ca2+ uptake into the sarcoplasmic reticulum |
| 09/15/2009 | US7588755 Immunomodulation by administration of a recombinant polypeptide produced by a non-human host transformed by a recombinant DNA molecule ; antiviral and antitumor or anticancer agents |
| 09/15/2009 | US7588752 Derived from milk protein casein; for use in dentistry |
| 09/15/2009 | CA2473991C Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor |
| 09/15/2009 | CA2451233C Stackable low depth tray |
| 09/15/2009 | CA2438663C Cyclic peptide |
| 09/15/2009 | CA2421683C Microparticles for delivery of the heterologous nucleic acids |
| 09/15/2009 | CA2419397C Novel use of a peptide class of compound for treating non neuropathic inflammatory pain |
| 09/15/2009 | CA2411233C Use of hyaluronidase for preventing and treating cardio vascular diseases |
| 09/15/2009 | CA2408417C Local anesthetic methods and kits |
| 09/15/2009 | CA2379696C Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine |
| 09/15/2009 | CA2371462C Modified protein matrices |
| 09/15/2009 | CA2369616C Somatic transgene immunization and related methods |
| 09/15/2009 | CA2342985C Hydroxamate-containing cysteine and serine protease inhibitors |
| 09/15/2009 | CA2270423C Prophylactic/therapeutic agent |
| 09/15/2009 | CA2218699C 1,3-propane diol derivatives as bioactive compounds |
| 09/15/2009 | CA2156272C Dna encoding a human neuropeptide y/peptide yy/pancreatic polypeptide receptor (y4) and uses thereof |
| 09/15/2009 | CA2149925C Peptidic derivates of .alpha.-msh and their uses |
| 09/15/2009 | CA2032158C Multivalent repressor of gene function |
| 09/11/2009 | WO2009111793A2 Subdermal tissue remodeling using myostatin, methods and related systems |
| 09/11/2009 | WO2009111727A1 Compositions comprising ghrh and gnrh and methods of using the same |
| 09/11/2009 | WO2009111698A1 Improved anticancer treatments |
| 09/11/2009 | WO2009111649A2 Methods and compositions for delivery of exogenous factors to nervous system sites |
| 09/11/2009 | WO2009111625A2 Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis |
| 09/11/2009 | WO2009111083A2 In vivo temporal control of activ at able matrix- degrading enzymes |
| 09/11/2009 | WO2009110952A2 Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices |
| 09/11/2009 | WO2009110947A2 Compositions and methods for inhibiting cytokine production |
| 09/11/2009 | WO2009110944A1 Modified toxins |
| 09/11/2009 | WO2009110504A1 Soybean protein material for patients with renal disease and foods made from the same |
| 09/11/2009 | WO2009110324A1 Method for regulation of expression of low-density lipoprotein receptor, and enhancer of expression of low-density lipoprotein receptor |
| 09/11/2009 | WO2009109927A2 Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer |
| 09/11/2009 | WO2009109649A1 Improved antitumoral treatments |
| 09/11/2009 | WO2009109643A2 Use of interleukin-1 conjugates in the treatment of diabetes |
| 09/11/2009 | WO2009109615A1 Novel crustacean androgenic gland hormone |
| 09/11/2009 | WO2009109532A2 Use of defensins against tuberculosis |
| 09/11/2009 | WO2009109359A1 Protein or glycoprotein from haliotis midae and its use as an immunotherapy agent |
| 09/11/2009 | WO2009109156A2 Novel antimicrobial peptides and their application |
| 09/11/2009 | WO2009109146A1 Use of hepatocyte nuclear factor 4α(hnf4α) for the treatment of human malignant solid tumors through induction-differentiation therapy |
| 09/11/2009 | WO2009109129A1 A new type of consensus interferon and preparation method thereof |
| 09/11/2009 | WO2009091645A3 Compositions and methods for treating chondrosarcomas |
| 09/11/2009 | WO2009089635A9 Treating neurodegenerative diseases with progranulin (pgrn) |
| 09/11/2009 | WO2009086131A4 Bmp mutants with decreased susceptibility to noggin |
| 09/11/2009 | WO2009081374A3 Cosmetic use of plakoglobin-type proteins |
| 09/11/2009 | WO2009075836A3 Rap variants for drug delivery |
| 09/11/2009 | WO2009067639A4 Variants of c-type natriuretic peptide |
| 09/11/2009 | WO2009052323A3 Manufacture, compositions and uses of coagulationfactor viia modulator |
| 09/11/2009 | WO2009046865A3 Cholecystokinin-33 alone or in combination with trap-14 as therapeutic agent |
| 09/11/2009 | WO2009040069A3 Use of bq-610 alone or in combination with helodermin as a therapeutic agent |
| 09/11/2009 | WO2009033821A3 Use of a peptide as a therapeutic agent |
| 09/11/2009 | WO2009033779A3 Nociceptin for use as a therapeutic agent |
| 09/11/2009 | WO2009033778A3 Mage-3 antigen and others for use as a therapeutic agent |
| 09/11/2009 | WO2009033775A3 Peptide alpmhir alone or in combination with peptide yvpfppf as therapeutic agent |
| 09/11/2009 | WO2009033732A3 Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent |
| 09/11/2009 | WO2009033729A3 Therapeutic uses of gastrin- 1 and g- pen-grgdspca |
| 09/11/2009 | WO2009033726A3 Use of cart (55-102), optionally in combination with tuftsin, as a therapeutic agent |
| 09/11/2009 | WO2009033683A3 Galanin message associated peptide alone or in combination with minigastrin as a therapeutic agent |
| 09/11/2009 | WO2009030065A8 INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION |
| 09/11/2009 | WO2008152507A3 Compositions and methods for treating ophthalmic disorders |
| 09/11/2009 | WO2008120085A3 Angiogenic composition |
| 09/11/2009 | WO2008115880A3 Use of leptin for the treatment or prevention of parkinson's disease |
| 09/11/2009 | WO2007023509A3 Cationic peptides forming amphipathic helices |
| 09/11/2009 | WO2004035811A3 Kinase modulation assay |
| 09/11/2009 | CA2718549A1 In vivo temporal control of activatable matrix-degrading enzymes |
| 09/11/2009 | CA2717736A1 Modulation of srpx2-mediated angiogenesis |
| 09/11/2009 | CA2717409A1 Improved anticancer treatments |
| 09/11/2009 | CA2717325A1 Novel crustacean androgenic gland hormone |
| 09/11/2009 | CA2717117A1 Improved antitumoral treatments |
| 09/11/2009 | CA2717108A1 Use of interleukin-1 conjugates in the treatment of diabetes |
| 09/11/2009 | CA2717006A1 Use of defensins against tuberculosis |
| 09/11/2009 | CA2710964A1 Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices |
| 09/10/2009 | US20090228997 Extracellular novel RAGE binding protein ( EN-RAGE) and uses thereof |